BRL launches InCellDx's HPV mRNA Test

Bio-Reference Laboratories announced this week that its GenPath Women's Health division has launched a new test called GenCerv.

The test is based on InCellDx's patented and proprietary HPV mRNA quantification technology. GenCerv will quantify E6 and E7 oncogene overexpression in distinct cell types, which, according to BRL, will help doctors diagnose HPV and identify patients whose disease will not progress to cervical cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.